Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method (Details) € / shares in Units, € in Thousands |
6 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Sep. 26, 2023
¥ / shares
shares
|
Sep. 26, 2023
€ / shares
shares
|
Jun. 30, 2025
EUR (€)
|
Jun. 30, 2024
EUR (€)
|
Dec. 31, 2024 |
|
Investments accounted for using the equity method | |||||
Capital increase | € | € 57,370 | € 6 | |||
Hepalys Pharma, Inc | |||||
Investments accounted for using the equity method | |||||
Group's share in % | 15.00% | 15.00% | 15.00% | ||
Catalys Option Agreement | Hepalys Pharma, Inc | |||||
Investments accounted for using the equity method | |||||
Option to acquire shares in company, percentage | 30.00% | 30.00% | |||
Number of shares acquired in associate | shares | 1,500,000 | 1,500,000 | |||
Purchase of interests in investments accounted for using equity method, price per share | (per share) | ¥ 300 | € 1.9 |